Search research articles
Contact Us
Filters
Showing results (1301-1310 of 1,392) with videos related to
Page
of 140
Sort By:
Advanced Biology
|
March 28, 2022
Understanding Suboptimal Response to Immune Checkpoint Inhibitors
Mojun Zhu, Henan Zhang, Katrina S Pedersen, et al.
The Lancet. Oncology
|
April 20, 2023
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Jianming Xu, Ken Kato, Eric Raymond, et al.
Cancer
|
March 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma
Lisa A Kachnic, Jennifer Moughan, Theodore S Hong, et al.
International Journal of Cancer
|
March 19, 2021
Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma
Lionel A Kankeu Fonkoua, Sakti Chakrabarti, Mohamad B Sonbol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 2, 2021
Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance])
Harry H Yoon, Fang-Shu Ou, Gamini S Soori, et al.
Journal De Mycologie Medicale
|
September 5, 2017
Risk factors for suboptimal drug concentration of posaconazole oral suspension in patients with hematologic malignancy
E J Kim, K-S Yu, S H Na, et al.
Annals of Surgical Oncology
|
February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Charles H Yoon, Merrick I Ross, Brian R Gastman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 19, 2021
Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report
Hee J Kim, Woo C Noh, Seok J Nam, et al.
Cancer Discovery
|
May 7, 2020
Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
Cécile Gstalder, David Liu, Diana Miao, et al.
Page
of 140
Search research articles
Search
Showing results (1301-1310 of 1,392) with videos related to
Sort By:
Page
of 140
Advanced Biology
|
March 28, 2022
Understanding Suboptimal Response to Immune Checkpoint Inhibitors
Mojun Zhu, Henan Zhang, Katrina S Pedersen, et al.
The Lancet. Oncology
|
April 20, 2023
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Jianming Xu, Ken Kato, Eric Raymond, et al.
Cancer
|
March 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma
Lisa A Kachnic, Jennifer Moughan, Theodore S Hong, et al.
International Journal of Cancer
|
March 19, 2021
Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma
Lionel A Kankeu Fonkoua, Sakti Chakrabarti, Mohamad B Sonbol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 2, 2021
Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance])
Harry H Yoon, Fang-Shu Ou, Gamini S Soori, et al.
Journal De Mycologie Medicale
|
September 5, 2017
Risk factors for suboptimal drug concentration of posaconazole oral suspension in patients with hematologic malignancy
E J Kim, K-S Yu, S H Na, et al.
Annals of Surgical Oncology
|
February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Charles H Yoon, Merrick I Ross, Brian R Gastman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 19, 2021
Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report
Hee J Kim, Woo C Noh, Seok J Nam, et al.
Cancer Discovery
|
May 7, 2020
Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
Cécile Gstalder, David Liu, Diana Miao, et al.
Page
of 140